WO2012153704A1 - 同位体を有するリン酸化合物の製造方法 - Google Patents
同位体を有するリン酸化合物の製造方法 Download PDFInfo
- Publication number
- WO2012153704A1 WO2012153704A1 PCT/JP2012/061652 JP2012061652W WO2012153704A1 WO 2012153704 A1 WO2012153704 A1 WO 2012153704A1 JP 2012061652 W JP2012061652 W JP 2012061652W WO 2012153704 A1 WO2012153704 A1 WO 2012153704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isotope
- trivalent phosphorus
- sugar
- production method
- phosphorus
- Prior art date
Links
- -1 phosphate compound Chemical group 0.000 title claims abstract description 71
- 229910019142 PO4 Inorganic materials 0.000 title claims abstract description 31
- 239000010452 phosphate Substances 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims description 38
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 101
- 239000011574 phosphorus Substances 0.000 claims abstract description 101
- 239000007800 oxidant agent Substances 0.000 claims abstract description 49
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 35
- 230000001590 oxidative effect Effects 0.000 claims abstract description 35
- 230000003647 oxidation Effects 0.000 claims abstract description 29
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 claims abstract 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 72
- 239000000178 monomer Substances 0.000 claims description 37
- 229920000642 polymer Polymers 0.000 claims description 27
- 239000002777 nucleoside Substances 0.000 claims description 24
- 238000010168 coupling process Methods 0.000 claims description 21
- 230000008878 coupling Effects 0.000 claims description 20
- 238000005859 coupling reaction Methods 0.000 claims description 20
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 20
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 20
- 125000001369 canonical nucleoside group Chemical group 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910000085 borane Inorganic materials 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 239000011593 sulfur Substances 0.000 claims description 12
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 11
- 229910052796 boron Inorganic materials 0.000 claims description 11
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- 239000003905 agrochemical Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 150000002978 peroxides Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- YRDSDHFBUHFDPG-UHFFFAOYSA-N n,n-dimethyl-n'-(5-sulfanylidene-1,2,4-dithiazol-3-yl)methanimidamide Chemical compound CN(C)C=NC1=NC(=S)SS1 YRDSDHFBUHFDPG-UHFFFAOYSA-N 0.000 claims description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical group CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 41
- 108020004707 nucleic acids Proteins 0.000 abstract description 20
- 102000039446 nucleic acids Human genes 0.000 abstract description 20
- 150000007523 nucleic acids Chemical class 0.000 abstract description 20
- 230000015572 biosynthetic process Effects 0.000 abstract description 15
- 238000003786 synthesis reaction Methods 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 5
- DWXQHSSGDGWIMP-UHFFFAOYSA-N borane N-ethyl-N-propan-2-ylpropan-2-amine Chemical compound B.CCN(C(C)C)C(C)C DWXQHSSGDGWIMP-UHFFFAOYSA-N 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 65
- 108020004459 Small interfering RNA Proteins 0.000 description 61
- 239000002585 base Substances 0.000 description 34
- 239000003184 complementary RNA Substances 0.000 description 25
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 25
- 235000021317 phosphate Nutrition 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 108020005544 Antisense RNA Proteins 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 150000002500 ions Chemical group 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101100281953 Homo sapiens GAPDH gene Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000001142 circular dichroism spectrum Methods 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 229910052792 caesium Inorganic materials 0.000 description 5
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000012096 transfection reagent Substances 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000030570 cellular localization Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229910052730 francium Inorganic materials 0.000 description 4
- KLMCZVJOEAUDNE-UHFFFAOYSA-N francium atom Chemical compound [Fr] KLMCZVJOEAUDNE-UHFFFAOYSA-N 0.000 description 4
- 102000047486 human GAPDH Human genes 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052701 rubidium Inorganic materials 0.000 description 4
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 4
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical group [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 239000005922 Phosphane Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910000064 phosphane Inorganic materials 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DBZQFUNLCALWDY-PNHWDRBUSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DBZQFUNLCALWDY-PNHWDRBUSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- UAQOYBJXXMLVQI-UHFFFAOYSA-N 5-methyl-1h-pyrimidin-2-one Chemical compound CC1=CN=C(O)N=C1 UAQOYBJXXMLVQI-UHFFFAOYSA-N 0.000 description 1
- SHLJOANTPJWIHS-UHFFFAOYSA-N 5-methyl-1h-pyrimidin-6-one Chemical compound CC1=CN=CNC1=O SHLJOANTPJWIHS-UHFFFAOYSA-N 0.000 description 1
- SDIZCZTVHWHHHX-UHFFFAOYSA-N 5-methyl-2-(sulfanylidenemethylidene)-1h-pyrimidin-4-one Chemical compound CC1=CNC(=C=S)NC1=O SDIZCZTVHWHHHX-UHFFFAOYSA-N 0.000 description 1
- OWKFQGDPRUUKOJ-UHFFFAOYSA-N 5-methyl-6-methylsulfanyl-1h-pyrimidin-2-one Chemical compound CSC=1NC(=O)N=CC=1C OWKFQGDPRUUKOJ-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- IKZRFGGARFKJOA-UHFFFAOYSA-N 7h-purin-8-amine Chemical compound C1=NC=C2NC(N)=NC2=N1 IKZRFGGARFKJOA-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- XZPVJGDMALVTDU-UHFFFAOYSA-N CC(C)NN(NC(C)C)P(Cl)(=O)CCC#N Chemical compound CC(C)NN(NC(C)C)P(Cl)(=O)CCC#N XZPVJGDMALVTDU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- UUGITDASWNOAGG-CCXZUQQUSA-N cyclouridine Chemical compound O=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 UUGITDASWNOAGG-CCXZUQQUSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- UPWHZOYYXHKXLQ-BGPJRJDNSA-N nucleoside triphosphate Chemical compound C[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O UPWHZOYYXHKXLQ-BGPJRJDNSA-N 0.000 description 1
- 150000008427 organic disulfides Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000008301 phosphite esters Chemical class 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
Definitions
- the present invention relates to a method for producing a phosphate compound having an isotope.
- a labeled compound into which an isotope is introduced As a method for confirming the behavior of a compound in a living body, it is common to use a labeled compound into which an isotope is introduced.
- the compound include nucleic acids such as DNA and RNA, and the use of stable isotopes has attracted attention because the isotopes do not affect living organisms.
- the synthesis of a nucleic acid into which a stable isotope is introduced is generally carried out by introducing a stable isotope into a monomer in advance and using this as a raw material to synthesize a polynucleotide.
- a stable isotope In order to detect stable isotopes with high sensitivity, it is desired that a large number of stable isotopes be introduced into the polynucleotide.
- this method in order to introduce a large number of stable isotopes, it is necessary to label all monomers including A, G, C and T / U bases, which is labor intensive and costly. There is a problem that becomes extremely high.
- Non-Patent Document 1 As a method of introducing a stable isotope, 2,2' cyclo uridine was opened by acid (PhC 18 O 2 H), at the 2 'position of the sugar, the hydroxyl group with a stable isotope (- 18 OH) Has been disclosed (Non-Patent Document 1).
- a nucleoside having a specific pyrimidine base can only be labeled, and a nucleoside having another base cannot be obtained.
- the labor and cost problems of labeling with a stable isotope are not limited to the nucleic acid, and the same applies to, for example, low molecular compounds such as pharmaceuticals and agricultural chemicals.
- an object of the present invention is to provide a method for easily producing a phosphate compound having an isotope.
- the production method of the present invention is a production method of a phosphate compound having an isotope, wherein the isotope is oxidized by oxidizing a trivalent phosphorus compound with an oxidizing agent containing an isotope. It includes an oxidation step of synthesizing a pentavalent phosphate compound into which is introduced.
- a phosphate compound containing an isotope can be easily produced only by using the oxidizing agent containing the isotope.
- the production method of the present invention is useful, for example, for the synthesis of a nucleic acid having a phosphate group and the synthesis of a low-molecular compound such as an agrochemical, a pharmaceutical or a phospholipid having a phosphate group.
- FIG. 1 is a mass spectrometry chromatogram of 18 O-labeled poly (U) in Example 1.
- FIG. FIG. 2 is a mass spectrometry chromatogram of 18 O-labeled poly (U) treated at a predetermined pH in Example 1.
- FIG. 3 is a photograph of Native-PAGE of siRNA introduced with 18 O in Example 2.
- 4 is a graph showing a circular dichroism spectrum of siRNA introduced with 18 O in Example 2.
- FIG. FIG. 5 is a graph showing the relative value of the expression level of human GAPDH gene mRNA in Example 2.
- FIG. 6 is a graph showing the relationship between the concentration of 18 O-labeled poly (U) and ⁇ 18 O [ ⁇ ] in Example 3.
- FIG. 7 is a photograph observing the intracellular localization of siRNA introduced with 18 O in Example 4.
- the production method of the present invention is a method for producing a phosphate compound having an isotope, and the trivalent phosphorus compound is converted into an oxidant containing an isotope (hereinafter referred to as “isotope oxidant”). It includes an oxidation step of synthesizing a pentavalent phosphate compound into which the isotope is introduced by oxidation.
- trivalent phosphorus of a trivalent phosphorus compound is oxidized to pentavalent phosphorus by the isotope oxidant, and accordingly, the isotope derived from the isotope oxidant is converted to the pentavalent phosphorus.
- the body joins.
- a pentavalent phosphate compound into which an isotope is introduced can be obtained only by performing an oxidation reaction with the isotope oxidant.
- the present invention is characterized in that the trivalent phosphorus compound is oxidized using the isotope oxidant, and other configurations and other conditions are not particularly limited.
- the production method of the present invention includes, for example, synthesis of agrochemicals having a phosphate group, pharmaceuticals, phospholipids and the like, nucleic acids such as RNA and DNA having a phosphate group, and nucleoside-monophosphate that is a monomer, It is preferably applied to the synthesis of nucleoside-diphosphate, nucleoside-triphosphate, and the like, particularly preferably applied to the synthesis of the nucleic acid.
- the method for synthesizing the nucleic acid is not limited at all, and examples thereof include a phosphite method, a phosphoramidite method (or also referred to as a phosphoramidite method) (hereinafter, amidite method) and the like.
- a phosphite method or also referred to as a phosphoramidite method
- amidite method a phosphoramidite method
- the amidite method will be described as an example, but the present invention is not limited to this.
- the amidite method In solid phase synthesis of nucleic acids, the amidite method generally removes the monomer amidite coupling step, the resulting oxidation step of trivalent phosphorus to pentavalent phosphorus (phosphate group) and the sugar protecting group at the 5 ′ end. One cycle of the deprotection step is repeated until the desired length is reached.
- the isotope can be easily introduced into the phosphate group of the phosphodiester bond only by using the isotope oxidant in the oxidation step. Moreover, the isotope can be introduced only into the desired phosphodiester bond by using the isotope oxidant only in the oxidation step of the desired cycle. Furthermore, the isotopes can be introduced into the phosphate groups of all phosphodiester bonds by using the isotope oxidant in the oxidation steps of all cycles. Conventionally, as described above, since it is necessary to synthesize an amidite into which an isotope is introduced for each base to be labeled, there is a problem that labor and cost are required.
- the oxidation reaction by the oxidizing agent is, for example, an oxidation reaction in which trivalent phosphorus in the trivalent phosphorus compound is oxidized to pentavalent phosphorus, and atoms derived from the oxidizing agent are bound to the pentavalent phosphorus. is there.
- the isotope oxidant may be such that the atom bonded to the pentavalent phosphorus is the isotope.
- the isotope oxidant is not particularly limited, and for example, oxidizes trivalent phosphorus in the trivalent phosphorus compound to pentavalent phosphorus and donates atoms to the pentavalent phosphorus. What is necessary is just to have an isotope as an atom donated to the pentavalent phosphorus.
- oxidizing agent exhibiting such an oxidation reaction from the common general knowledge at the time of filing, and for the oxidizing agent having an isotope as the donated atom, for example, a commercially available product can be obtained. It can be manufactured from the common general knowledge at the time of filing.
- the isotope is not particularly limited, and may be, for example, a stable isotope or a radioactive isotope, preferably the former. If it is the said stable isotope, since there is little danger of exposure and a dedicated facility is unnecessary, it is excellent in handling property and can also reduce cost. In addition, the stable isotope is different from, for example, a fluorescent label, has no change in physical properties of the labeled compound, and is excellent in properties as a tracer.
- the isotope oxidant is not particularly limited, and examples thereof include oxygen donors that donate isotope oxygen to pentavalent phosphorus by oxidation.
- examples of the isotope include 17 O, 18 O, and the like, and preferably 18 O.
- Examples of the oxygen donor include water or peroxide (peroxide) having isotope oxygen.
- the peroxide is represented, for example, by the chemical formula R—O—O—R ′, and R and R ′ are, for example, H or an optional substituent. R and R 'may be the same or different.
- the substituent is not particularly limited, and examples thereof include an alkyl group having 1 to 10 carbon atoms, and may be linear or branched. Examples of the alkyl group include a butyl group such as a t-butyl group.
- Examples of the peroxide include a hydroperoxide in which at least one of R and R 'is preferably hydrogen, halogen or a monovalent metal, and more preferably at least one of R and R' is hydrogen. Examples of the hydroperoxide include t-butyl hydroperoxide.
- Examples of the monovalent metal include alkali metals such as sodium, potassium, lithium, rubidium, cesium, and francium.
- the oxygen donor is particularly preferably H 2 18 O having 18 O because, for example, a commercially available product with high purity can be obtained.
- water having the isotope oxygen for example, it is preferable to use iodine (I 2 ), pyridine (Py), and tetrahydrofuran (THF) in combination.
- the pentavalent phosphoric acid compound obtained for example, a pentavalent phosphorus, hydroxyl groups isotope oxygen - is preferably (18 OH) are attached,
- the hydrogen in the hydroxyl group may be substituted with a monovalent metal such as an alkali metal, for example. Examples of the alkali metal include sodium, potassium, lithium, rubidium, cesium, francium and the like.
- isotope oxidizing agent examples include a sulfur donor that donates isotope sulfur to pentavalent phosphorus by oxidation.
- examples of the isotope include 33 S, 34 S, 36 S and the like, and 34 S is preferable.
- the sulfur donor is preferably, for example, a disulfide having isotope sulfur (compound having —SS—), more preferably an organic disulfide, and still more preferably a cyclic organic disulfide.
- the disulfide include, for example, 3H-1,2-benzothiol 3-one 1,1-dioxide, 5-((dimethylamino-methylidene) amino) -3H-1,2,4-dithiazole-3- Thion and the like are preferable, preferably 3H-1,2-benzodithyl 3-one 1,1-dioxide, more preferably 3H-1,2-benzodithyl 3-one 1,1-dioxide having 34 S. is there.
- the obtained pentavalent phosphate compound has, for example, isotope sulfur bonded to pentavalent phosphorus, specifically, phosphorothioate. Is preferably formed.
- Examples of the isotope oxidizing agent include boron donors that donate isotope boron to pentavalent phosphorus by oxidation.
- Examples of the isotope include 10 B.
- the boron donor is preferably an amine-borane complex having an isotope boron, and more preferably a trialkylamine-borane complex.
- the trialkylamine / borane complex include diisopropylethylamine (DIPEA) / borane complex represented by C 8 H 19 N ⁇ BH 3 , preferably DIPEA / borane complex C having 10 B.
- pentavalent phosphoric acid compound obtained, for example, a pentavalent phosphorus, borane group having isotope boron (- 10 BH 3 -) is a bond Specifically, it is preferable to form boranophosphate.
- hydrogen of the borane group may be substituted with halogen, for example. Examples of the halogen include F, Cl, Br, and I.
- the borane group may form a salt with a monovalent metal or a divalent metal, for example.
- Examples of the monovalent metal include alkali metals such as sodium, potassium, lithium, rubidium, cesium, and francium.
- the divalent metal is, for example, an alkaline earth metal, and examples thereof include calcium, strontium, barium, and radium.
- the trivalent phosphorus compound is not particularly limited as long as it is a compound having trivalent phosphorus.
- Examples of the trivalent phosphorus compound include phosphorous acid and phosphite.
- the phosphorous acid includes, for example, phosphite, phosphorous acid derivatives and the like in addition to phosphorous acid [HP (O) (OH) 2 ].
- phosphoric acid in which an isotope is bound to phosphorus can be produced by using phosphorous acid as the trivalent phosphorus compound.
- the obtained phosphoric acid includes, for example, the meanings of phosphates, phosphoric acid derivatives and the like.
- phosphites examples include phosphite monoester [R 1 O—P (OX 2 ) —OX 3 ], phosphite diester [R 1 O—P (OR 2 ) —OX 3 ], phosphorous Any of acid triester [R 1 O—P (OR 2 ) —OR 3 ] may be used.
- X 2 and X 3 are, for example, hydrogen or a monovalent metal.
- the monovalent metal is, for example, an alkali metal, and examples thereof include sodium, potassium, lithium, rubidium, cesium, and francium.
- the R 1 , R 2 and R 3 are not limited at all, and various organic groups such as a hydrocarbon group described later can be mentioned.
- the nucleic acid may be, for example, a monomer or a polymer obtained by polymerizing the monomer.
- Examples of the monomer include nucleotides constituting RNA or DNA.
- a pentavalent phosphate group is bonded to a nucleoside composed of a sugar and a base.
- the nucleotide has a sugar, a base, and a pentavalent phosphate group, and the base is bonded to the 1 ′ position of the sugar, and the 5 ′ position, the 3 ′ position, or the 2 ′ position of the sugar.
- the pentavalent phosphate group is bonded to each other.
- Specific examples of the nucleotide include ribonucleotides and deoxyribonucleotides.
- the nucleotide includes, for example, the meaning of a derivative of the nucleotide.
- the polymer is, for example, a polymer of the nucleotide, specifically, RNA that is a polymer of ribonucleotides, DNA that is a polymer of deoxyribonucleotides, or a polymer of ribonucleotides and deoxyribonucleotides (DNA / RNA Chimera) and the like.
- the polymerization number of the monomer is not limited, and includes the meaning of an oligomer.
- a sugar of one nucleotide and a sugar of the other nucleotide are bonded through the phosphate group.
- the 5′-position, 3′-position or 2′-position of one sugar and the 5′-position, 3′-position or 2′-position of the other sugar are It is preferable that they are bonded via a phosphate group.
- the combination of the binding sites of the sugar of one nucleotide and the sugar of the other nucleotide is not particularly limited, the combination of the 5 ′ position and the 3 ′ position, the combination of the 5 ′ position and the 5 ′ position, and the 3 ′ position. And the combination of the 3 ′ position and the combination of the 2 ′ position and the 5 ′ position.
- the sugar may be, for example, ribose having a hydroxy group bonded to the 2′-position carbon atom, or deoxyribose having a hydrogen atom bonded to the 2′-position carbon atom.
- the hydroxy group may be substituted (modified) with any atom or group.
- the atom include a hydrogen atom and a halogen atom, and examples of the halogen atom include F, Cl, Br, and I. Among these, F (fluorine atom) is preferable.
- Examples of the group include an alkoxy group (—O-alkyl group), an acyloxy group (—O-acyl group), an amino group (NH 2 group), or a substituted amino group in which H is substituted with a substituent. It is done.
- the alkoxy group (—O-alkyl group) is not particularly limited, and examples thereof include a methoxy group (—O-Me group), and the alkyl group is not limited.
- the acyloxy group (—O-acyl group) is not particularly limited, and examples thereof include —O—CHO group, and the acyl group is not limited.
- the hydrogen atom may be substituted (modified) with an arbitrary atom. Examples of the atom include the halogen atom and the like.
- the base is not particularly limited, and examples thereof include adenine, guanine, cytosine, thymine, uracil and the like.
- examples of these substituted bases include 7-deazaguanine, 7-deaza-8-azaguanine, and 5-propynylcytosine.
- the base may be, for example, a natural base or a non-natural base.
- a nucleoside having the trivalent phosphorus is oxidized with the isotope oxidizing agent. According to this method, the trivalent phosphorus bonded to the nucleoside is converted into the pentavalent phosphorus by oxidation, and the isotope derived from the isotope oxidant is bonded to the pentavalent phosphorus. For this reason, the monomer which has an isotope can be obtained.
- the nucleoside having trivalent phosphorus preferably includes, for example, a sugar and a base, a base is bonded to the 1′-position of the sugar, and the trivalent phosphorus is bonded to the sugar.
- the trivalent phosphorus is bonded to the 5′-position, 3′-position or 2′-position of the sugar.
- the nucleoside having trivalent phosphorus is, for example, the phosphite, specifically, phosphite monoester [R 1 O—P (OX 2 ) —OX 3 ], phosphorus It can be represented by either an acid diester [R 1 O—P (OR 2 ) —OX 3 ] or a phosphorous acid triester [R 1 O—P (OR 2 ) —OR 3 ]. Any of R 1 , R 2 and R 3 is preferably the nucleoside.
- the trivalent phosphorus compound for example, a polymer containing a nucleoside residue having trivalent phosphorus synthesized in advance is used as the trivalent phosphorus compound, and this is oxidized with the isotope oxidant to introduce an isotope.
- the trivalent phosphorus in the polymer becomes the pentavalent phosphorus by oxidation, and the isotope derived from the isotope oxidant is bonded to the pentavalent phosphorus, so that a polymer having an isotope can be obtained. it can.
- the polymer having trivalent phosphorus is a polymer containing two or more nucleoside residues.
- the nucleoside residue contains a sugar and a base, the base is bonded to the 1'-position of the sugar, and each sugar is bonded via phosphorus between the nucleoside residues.
- the 5′-position, 3′-position or 2′-position of one sugar and the 5′-position, 3′-position or 2′-position of the other sugar are phosphorous. It is preferable that it couple
- the combination of the binding sites of the sugar of one nucleotide and the sugar of the other nucleotide is not particularly limited, the combination of the 5 ′ position and the 3 ′ position, the combination of the 5 ′ position and the 5 ′ position, and the 3 ′ position. And the combination of the 3 ′ position and the combination of the 2 ′ position and the 5 ′ position.
- the phosphorus between at least one pair of nucleoside residues is the trivalent phosphorus.
- at least one of the phosphorus between the nucleoside residues may be trivalent phosphorus or all may be trivalent phosphorus.
- the trivalent phosphorus compound is, for example, the phosphite as described above.
- the phosphite is, for example, either a phosphite diester [R 1 O—P (OR 2 ) —OX 3 ] or a phosphite triester [R 1 O—P (OR 2 ) —OR 3 ]. It can be expressed as R 1 and R 2 are preferably the nucleoside residue or a polymer of the nucleoside residue, and both may be the same or different.
- the polymer may be, for example, a polymer (polynucleotide) in which the nucleotide residue is phosphodiester linked, or the nucleotide residue is trivalent. A polymer bonded via phosphorus may also be used.
- the number of nucleotide residues constituting the polymer is not limited.
- the second method is, for example, a method of performing nucleoside coupling and isotope introduction by oxidation using the isotope oxidant.
- the said isotope is introduce
- the method for synthesizing the polymer is not particularly limited, and examples thereof include a phosphite method and an amidite method. These synthesis methods may be, for example, solid phase synthesis or liquid phase synthesis, and are not particularly limited.
- the second method further includes, for example, a coupling step of synthesizing the trivalent phosphorus compound by coupling two molecules of a monomer including a nucleoside, and in the oxidation step, the coupling is performed.
- the trivalent phosphorus compound obtained in the step is oxidized with the isotope oxidant to synthesize a pentavalent phosphate compound into which the isotope is introduced.
- the type of the monomer is not particularly limited, and a known monomer can be used.
- trivalent phosphorus is bonded to a site bonded to the other monomer, and a protecting group for the hydroxyl group is bonded to a site having another hydroxyl group.
- the site to which the trivalent phosphorus is bonded is not particularly limited, and examples thereof include the 5′-position, the 3′-position, and the 2′-position, and the site to which the protective group is bonded is not particularly limited, and is 5′-position, 3′-position. Position or 2 'position.
- the combination of the binding site of the trivalent phosphorus and the binding site of the protecting group is not particularly limited.
- the combination of the 5 ′ position and the 3 ′ position, the combination of the 5 ′ position and the 5 ′ position, and the 3 ′ position and 3 The combination of 'position', the combination of 2'position and 5'position, etc. can be mentioned.
- the one monomer has, for example, a trivalent phosphorus bonded to the 3 'position of the sugar of the nucleoside and a hydroxyl protecting group bonded to the 5' position of the sugar.
- the trivalent phosphorus preferably has a reactive group that reacts with a hydroxyl group.
- the protecting group is not particularly limited, and examples thereof include a dimethoxytrityl (DMTr) group.
- the site bonded to the one monomer is preferably a hydroxyl group from which the protecting group is removed.
- the site to be bonded to the one monomer is not particularly limited, and examples thereof include 5 'position, 3' position and 2 'position.
- the other monomer is preferably a hydroxyl group with the protecting group at the 5'-position of the sugar of the nucleoside removed.
- trivalent phosphorus is oxidized to pentavalent phosphorus, and a polymer in which the nucleoside is bonded by a phosphodiester bond having an isotope is synthesized.
- the monomer to which the protecting group is bonded is not particularly limited, and for example, monomers used in the phosphite method, the amidite method and the like as described above can be applied.
- Examples of the monomer for the amidite method include known phosphoramidites. Specific examples thereof include TBDMS-amidite, TOM-amidite, and ACE-amidite.
- the nucleoside is not particularly limited, and includes a sugar and a base as described above, and the base is bonded to the 1'-position of the sugar.
- the latter monomer is immobilized on a solid phase, for example, other than the binding site with the former monomer.
- the latter monomer is, for example, a monomer in which the 5'-position of the sugar is a hydroxyl group
- the 3'-position of the sugar is preferably immobilized on a solid phase.
- the second method may further include, for example, a deprotecting step of removing the protecting group (for example, the 5 'position) of the sugar of the nucleoside.
- the method of deprotection is not particularly limited, and can be performed by a known method, for example, depending on the type of protecting group.
- the method further comprises a coupling step of synthesizing the trivalent phosphorus compound by coupling a new monomer containing a nucleoside to the pentavalent phosphate compound, which is obtained by the coupling step.
- the obtained trivalent phosphorus compound may be oxidized with the isotope oxidant to synthesize a pentavalent phosphate compound into which the isotope is introduced.
- the isotope can be introduced into the desired phosphodiester bond by repeatedly performing the coupling step and the oxidation step and using the isotope oxidant in the desired oxidation step or all the oxidation steps.
- a new monomer is coupled to the pentavalent phosphate compound, for example, after deprotecting a sugar protecting group (for example, the 5 ′ position) on the 5′-terminal nucleoside of the pentavalent phosphate compound. It is preferable to couple the monomers. That is, in the second method, it is preferable to repeat the coupling step, the oxidation step, and the deprotection step. The number of repetitions is not limited at all, and can be performed until the desired polymer length is obtained.
- R at the 2′-position of the sugar is not particularly limited, and examples thereof include the hydrocarbon groups described above.
- R at the 2′-position of the sugar is not particularly limited, and examples thereof include the hydrocarbon groups described above.
- R at the 2′-position of the sugar is not particularly limited, and examples thereof include the hydrocarbon groups described above.
- R at the 2′-position of the sugar is not particularly limited, and examples thereof include the hydrocarbon groups described above.
- ⁇ 18 OH can be introduced into the phosphate group, and 3H-1,2-benzodithyl 3-one 1 having 34 S can be introduced.
- the phosphate group - 34 S - can introduce, by oxidation with DIPEA ⁇ borane complex, a phosphate group - 10 BH 3 - can be introduced.
- agricultural chemicals, pharmaceuticals, phospholipids, and the like in which isotopes are introduced into phosphate groups can be produced.
- examples of the agrochemical include marathon and sumithion
- examples of the pharmaceutical include sodium hydrocortisone phosphate (trade name: Kraton).
- R is not limited at all, and examples thereof include the hydrocarbon groups as described above.
- R—OH and a trivalent phosphorus donor are reacted to synthesize a trivalent phosphorus compound.
- the trivalent phosphorus donor is not particularly limited.
- the following compounds having a cyano group include 2-cyanoethyl chloro (diisopropylamino) phosphinate (N, N-Diisopropylamino cyanoethyl phosphonamidic chloride) or 2-cyanoethyl.
- N, N, N, N-tetraisopropyl phosphane (2-Cyanoethyl N, N, N, N-tetraisopropyl phosphane).
- the pentavalent phosphate compound in which the isotope was introduced into X is obtained by performing the reaction 2 using the above-mentioned isotope oxidant.
- the isotope oxidant introduces, for example, the oxygen donor when introducing isotope oxygen into X, and the isotope boron when introducing isotope sulfur into X, and the sulfur donor when X is introduced. In this case, it is preferable to use the boron donor.
- the isotope-containing phosphate compound obtained by the production method of the present invention can be used in place of, for example, a conventional phosphate compound, and its use is not limited at all.
- RNA labeled with 18 O As a synthetic RNA, 18 O-labeled poly (U) having a base length of 20 mer in which one 18 O was introduced into each phosphate group of a phosphodiester bond was synthesized. Using TBDMS-amidite as a monomer raw material and using a nucleic acid synthesizer (trade name: ABI Expedite 8909, ABI) based on the phosphoramidite method, a coupling step, an oxidation step, and a ribose residue 5 ′ The deprotection step for removing the protective group dimethoxytrityl (DMTr) group at the position was repeated 19 cycles.
- DMTr dimethoxytrityl
- the composition used was a THF / pyridine / water mixture containing 0.1 mol / L iodine.
- the mixing ratio (volume ratio) of THF: pyridine: water was 78: 20: 2.
- the composition containing the H 2 18 O according to the conventional method.
- FIG. 1 is a chromatogram showing the results of mass spectrometry of synthetic RNA.
- the measured value of 18 O-labeled poly (U) was 6094.2.
- 18 O-labeled poly (U) was evaluated for pH stability. Specifically, 18 O-labeled poly (U) is mixed in a 50 mmol / L phosphate buffer solution having a predetermined pH (pH 3, 4, 5.5, 7, 8.5) so as to be 20 ⁇ mol / L. And incubated at 37 ° C. for 28 days. Then, the stability of the 18 O-labeled poly (U) after incubation was confirmed by analyzing the molecular weight using LC-ESI-Q-Tof-MS (trade name: Waters SYNAPT G2 MS). .
- LC-ESI-Q-Tof-MS trade name: Waters SYNAPT G2 MS.
- FIG. 2 is a chromatogram showing mass spectrometry results of 18 O-labeled poly (U) after incubation at each pH.
- FIG. 2 it is a result after processing by pH 3.0, 4.0, 5.5, 7.0, and 8.5 in an order from the upper graph.
- the molecular weight of 18 O-labeled poly (U) did not change from the molecular weight before incubation (actual measurement value: 6094.2) regardless of the pH.
- 18 O-labeled poly (U) was stable at pH 3 to 8.5. That is, it was confirmed that 18 O labeling was stable without being exchanged with water molecules (H 2 16 O) in the surrounding environment at pH 3 to 8.5. This indicates that the 18 O label is similarly stable in the biological environment, and the 18 O label has the necessary stability as a tracer.
- Example 2 (1) Synthesis of 18 O-labeled siRNA RNA having a length of 21 bases shown in the following SEQ ID NOs: 1 to 4 was synthesized by the same RNA synthesis method as in Example 1. In addition, the said coupling process, the said oxidation process, and the said deprotection process repeated 20 cycles by making these into 1 cycle. In each of these RNAs, one 18 O was introduced into each phosphate group of the phosphodiester bond by the RNA synthesis method. That is, 20 18 O was introduced into each RNA. On the other hand, RNAs of SEQ ID NOs: 1 to 4 were synthesized in the same manner except that unlabeled H 2 16 O was used as the oxidizing agent.
- the single-stranded RNAs into which 18 O was introduced were designated as target 18 O-sense RNA, target 18 O-antisense RNA, control 18 O-RNA sense, and control 18 O-antisense RNA, respectively. Further, 18 O is a single-stranded RNA having 16 O is not installed, respectively, 16 O-sense RNA target, 16 O-antisense RNA target control for 16 O-sense RNA, 16 for a control O -Antisense RNA.
- each RNA introduced with 18 O had a measured value that was very close to the theoretical value.
- the results, 18 O and introduced 21-base-long RNA, respectively, 18 O has proved to be introduced into the phosphodiester bond phosphate groups of 20 locations.
- the target sense RNA and the target antisense RNA are overhang sequences, and the target sense RNA and the target anti RNA
- the sense RNA is completely complementary with a length of 19 bases excluding the overhang.
- the following double strands of the target sense RNA and the target antisense RNA are siRNA (target 18 O-siRNA) against human GAPDH.
- the sense RNA is completely complementary with a length of 19 bases excluding the overhang.
- the double strands of the control sense RNA and the control antisense RNA are siRNAs (negative control 18 O-siRNA) that do not show RNA interference with human GAPDH.
- Double-stranded RNA was formed by combining the obtained single-stranded RNAs as shown below.
- control sense RNA and the control antisense RNA are overhang sequences
- the control sense RNA and the control antisense RNA are completely complementary in length of 19 bases excluding the overhang.
- the double strands of the control sense RNA and the control antisense RNA are siRNAs that do not exhibit RNA interference with human GAPDH.
- C1 a combination of the control for 16 O-sense RNA and the control for 16 O-antisense RNA (16 O / 16 O)
- C2 Combination of the control 16 O-sense RNA and the control 18 O-antisense RNA
- C3 Combination of the control 18 O-sense RNA and the control 16 O-antisense RNA
- C4 a combination of the control for 18 O-sense RNA and the control for 18 O-antisense RNA (18 O / 18 O)
- 2 bases (AG) at the 3 ′ end of the target sense RNA (SEQ ID NO: 1) and 2 bases (UU) at the 3 ′ end of the target antisense RNA (SEQ ID NO: 2) are overhang sequences.
- the target sense RNA and the target antisense RNA are completely complementary in length of 19 bases excluding the overhang.
- the following double strands of the target sense RNA and the target antisense RNA are siRNAs against human GAPDH.
- T1 combined with 16 O-antisense RNA for the the 16 O-sense RNA for the target target (16 O / 16 O)
- T2 Combination of the target 16 O-sense RNA and the target 18 O-antisense RNA
- T3 Combination of the target 18 O-sense RNA and the target 16 O-antisense RNA
- T4 combined with 18 O-antisense RNA for the the 18 O-sense RNA for the target target (18 O / 18 O)
- siRNAs (c1) to (c4) and (t1) to (t4) were subjected to electrophoresis by electrophoresis, and their respective molecular weights were confirmed.
- electrophoresis a 15% acrylamide gel was used for electrophoresis.
- FIG. 3 shows the results of confirmation of double strand formation of each siRNA.
- FIG. 3 is a photograph of Native-PAGE confirming the formation of each siRNA, lanes 1 to 4 are the control siRNAs of (c1) to (c4), and lanes 5 to 8 are the (t1) This is a target siRNA of (t4).
- the control siRNAs in lanes 1 to 4 showed the same molecular weight
- the target siRNAs in lanes 5 to 8 showed the same molecular weight. From this result, it was shown that RNA into which 18 O was introduced formed a double strand in the same manner as RNA into which 18 O had not been introduced and became siRNA.
- FIG. 4 shows the results of the CD spectrum.
- FIG. 4 shows (c4) control siRNA ( 18 O / 18 O) and (t4) target siRNA ( 18 ) among the siRNAs (c1) to (c4) and (t1) to (t4). O / 18 O) results are shown.
- the vertical axis represents ellipticity (molecular ellipticity) (millimeter: mdeg), and the horizontal axis represents wavelength (nm).
- FIG. 4 (A) the (c4) is the result of the control for siRNA (18 O / 18 O)
- FIG. 4 (B) the result of the (t4) siRNA target (18 O / 18 O) is there.
- control siRNA all show the same CD spectrum as the (c4) control siRNA in FIG. 4 (A), and the (t1) to (t3) target All siRNAs (not shown) showed the same CD spectrum as the (t4) target siRNA in FIG. 4B. From these results, it was confirmed that the four types of control siRNAs had the same structure and the four types of target siRNAs had the same structure. That, siRNA was introduced 18 O, has been shown to have the same structure as siRNA of 18 O is not installed.
- thermodynamic stability of siRNA The thermodynamic stability of each siRNA in (4) was confirmed.
- the thermodynamic stability (Tm value) was measured with a spectrophotometer (trade name UV-1800 UV-VIS, Shimadzu Corporation).
- Table 3 below shows the confirmation results of the thermodynamic stability. As shown in Table 3 below, for the target siRNA, it was confirmed that each siRNA showed the same thermodynamic stability. Moreover, it was confirmed that each siRNA exhibits the same thermodynamic stability for the control siRNA. Thus, 18 O was introduced siRNA is thermodynamic stability, it was found that the siRNA and the same degree of 18 O is not installed.
- HCT116 cells derived from human colon adenocarcinoma
- the culture conditions were 37 ° C. and 5% CO 2 .
- the medium used was McCoy's 5A medium supplemented with 10% inactivated calf serum.
- the cells were cultured in the above-mentioned medium, and the culture solution was dispensed into a 24-well plate in a volume of 400 ⁇ L at 4 ⁇ 10 4 cells / well.
- the siRNA was transfected into the cells using a transfection reagent (trade name Lipofectamine 2000, Invitrogen) according to the attached protocol. Specifically, 100 ⁇ L of the complex of siRNA and transfection reagent was added per well, the total amount was 500 ⁇ L, and the final concentration of siRNA was 0.1 nmol / L.
- the following primer sets were used for amplification of the GAPDH gene and ⁇ -actin gene, respectively.
- GAPDH gene amplification primer set 5'-GGAGAAGGCTGGGGCTCATTTGC-3 '(SEQ ID NO: 5) 5'-TGGCCAGGGGTGCTAAGCAGTTG-3 '(SEQ ID NO: 6)
- Primer set for ⁇ -actin gene amplification 5'-GCCACGGCTGCTTCCAGCTCCTC-3 '(SEQ ID NO: 7) 5'-AGGTCTTTGCGGATGTCCACGTCAC-3 '(SEQ ID NO: 8)
- the gene expression level was also measured for cells to which the siRNA and the transfection reagent were not added ( ⁇ ).
- the gene expression level was also measured for cells to which the siRNA was not added and only the transfection reagent was added (mock).
- FIG. 5 is a graph showing the relative expression level of human GAPDH gene mRNA, and the vertical axis represents the relative gene expression level.
- the siRNAs into which 18 O was introduced exhibited the same expression suppression activity as the target siRNA into which 18 O had not been introduced.
- the results, for the siRNA was introduced 18 O it was confirmed that can be used in the same manner as siRNA having 18 O 16 O is not installed.
- Example 3 The serum concentration of the 18 O-labeled poly (U) synthesized in Example 1 was measured.
- Serum samples were prepared by adding the 18 O-labeled poly (U) to the mouse pool serum to a predetermined concentration.
- the predetermined concentration is 0, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2 ⁇ g. / ML.
- the serum sample was lyophilized in a silver capsule. Then, the freeze-dried serum sample was subjected to a stable isotope ratio mass spectrometer connected to a gasification pretreatment apparatus.
- the gasification pretreatment apparatus used was TC / TA manufactured by Thermo Fisher Scientific, and the stable isotope ratio mass spectrometer used was VELTA V Plus manufactured by Thermo Fisher Scientific.
- ⁇ 18 O percentage: ⁇ .
- R (s) is a measured value of the 18 O / 16 O ratio of the serum sample
- R (r) is a measured value of the 18 O / 16 O ratio of the standard substance.
- ⁇ 18 O ( ⁇ ) [R (s) / R (r) ⁇ 1] ⁇ 1000
- FIG. 6 shows a graph of the correlation between the ⁇ 18 O value and the 18 O-labeled poly (U) concentration.
- the vertical axis represents the ⁇ 18 O value ( ⁇ )
- the horizontal axis represents the concentration of the 18 O-labeled poly (U).
- radioisotope-labeled RNA has been used as a method for measuring the blood concentration of RNA.
- radioisotopes are concerned about the danger of exposure.
- we use a stable isotope 18 O has been introduced RNA, as shown in FIG. 6, by 18 O-labeled RNA, in the blood, and RNA concentration It was confirmed that there was a correlation with the ⁇ 18 O value ( ⁇ ). For this reason, it can be seen that, by using RNA introduced with 18 O as RNA for pharmaceuticals or the like, for example, after administration to a living body, it is possible to maintain safety and measure blood concentration.
- Example 4 For the siRNA introduced with 18 O synthesized in Example 2, intracellular localization was observed using a stable isotope microscope.
- siRNA Using the a combination of said 18 O-sense RNA and 18 O-antisense RNA prepared in Example 2 (c4) control for siRNA (18 O / 18 O) .
- the cultured cells were washed with PBS and treated with a 2.5% glutaraldehyde / PBS solution at 37 ° C. for 1 hour to fix the cells. Thereafter, the fixed cells were dehydrated by immersing them in 20, 40, 60, 70, 80, 90, 100% ethanol in this order for 10 minutes. Then, tert-butanol was added to the dehydrated cells, frozen in a freezer and dried. The freeze-dried product was coated with a gold coating having a thickness of 30 nm. In this way, a sample was produced.
- FIG. 7 is a photomicrograph of the intracellular localization of the control siRNA ( 18 O / 18 O).
- the upper left photograph is a secondary ion image of 16 O
- the lower left photograph is a secondary ion image of 12 C 14 N
- the upper right photograph is a secondary ion image of 18 O.
- the lower right photograph is a secondary ion image of 18 O / 16 O.
- the secondary ion image of 12 C 14 N is an imaging of organic matter
- the morphology of the cells could be confirmed from the lower left photograph ( 12 C 14 N) in FIG.
- the strong portion of 16 O appears white and the weak portion appears black.
- the photograph ( 16 O) in the upper left of FIG. 7 is blackish as a whole, and thus it was confirmed that natural 16 O was present evenly.
- the 18 O secondary ion image the 18 O strong portion appears white and the weak portion appears black.
- the administered siRNA for control 18 O / 18 O
- the portion with a low 18 O ratio is blue and the portion with a high 18 O ratio is red.
- the portion corresponding to the white point in the upper right photograph ( 18 O) has a high 18 O / 16 O ratio and is imaged in red (white in the figure). Point), and other locations were imaged blue because the 18 O / 16 O ratio was around 0.002 natural. From these results, it can be seen that, when siRNA introduced with 18 O is used, for example, an image image showing the localization of the siRNA can be obtained from the 18 O / 16 O ratio without using a fluorescent label or the like. It was.
- fluorescently labeled nucleic acids are generally used for imaging.
- fluorescent substances are usually hydrophobic and have a large molecular weight, adding them to the ends of nucleic acids may cause the physical properties of the nucleic acids to differ from unmodified forms not modified with fluorescent labels. There is sex. Further, the fluorescent material may be cleaved in vivo.
- labeling with 18 O suppresses changes in the physical properties of the nucleic acid, can be modified to all phosphate groups, and can also prevent the modification from being removed. For this reason, by using a nucleic acid introduced with 18 O, for example, it is possible to observe the intracellular localization more efficiently.
- a phosphate compound containing an isotope can be easily produced only by using the oxidant containing the isotope.
- the production method of the present invention is useful, for example, for the synthesis of a nucleic acid having a phosphate group and the synthesis of a low-molecular compound such as an agrochemical, a pharmaceutical or a phospholipid having a phosphate group.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)18Oで標識されたRNAの合成
合成RNAとして、ホスホジエステル結合の各リン酸基に1つの18Oを導入した、塩基長20merの18O標識化ポリ(U)を合成した。モノマー原料として、TBDMS-アミダイトを使用し、核酸合成機(商品名ABI Expedite 8909、ABI社)を用いて、ホスホロアミダイト法に基づいて、カップリング工程、酸化工程、およびリボース残基の5’位の保護基ジメトキシトリチル(DMTr)基をはずす脱保護工程を1サイクルとして19サイクル繰り返した。全ての酸化工程において、同位体酸化剤として、同位体酸素18Oを有するH2 18O(WATER-18O、純度18O atom%=99.2%、大陽日酸株式会社)を含む組成物を使用した。前記組成物は、0.1mol/Lヨウ素を含むTHF/ピリジン/水の混合液を使用した。前記混合液において、THF:ピリジン:水の混合比(体積比)は、78:20:2とした。なお、前記H2 18Oを含む前記組成物を使用した以外は、定法に従った。
得られた18O標識化ポリ(U)について、定法に基づき、マトリックス支援レーザー脱離イオン化飛行時間型質量分析装置(商品名Bruker AUTOFLEX)を使用して分子量を測定した。
得られた18O標識化ポリ(U)について、pH安定性を評価した。具体的には、所定pH(pH3、4、5.5、7、8.5)の50mmol/Lリン酸緩衝液に、20μmol/Lとなるように18O標識化ポリ(U)を混合し、37℃で28日間インキュベートした。そして、インキュベート後の前記18O標識化ポリ(U)について、LC-ESI-Q-Tof-MS(商品名:Waters SYNAPT G2 MS)を用いて分子量を分析することにより、その安定性を確認した。
(1)18O標識化siRNAの合成
前記実施例1と同様のRNA合成方法により、下記配列番号1~4に示す21塩基長のRNAを合成した。なお、前記カップリング工程、前記酸化工程および前記脱保護工程は、これらを1サイクルとして20サイクル繰り返した。これらのRNAは、いずれも、前記RNA合成方法により、ホスホジエステル結合の各リン酸基に1つの18Oが導入された。つまり、各RNAは、20個の18Oが導入された。他方、酸化剤として、未標識のH2 16Oを使用した以外は、同様にして、配列番号1~4のRNAを合成した。
5’-CCAUGAGAAGUAUGACAACAG-3’ (配列番号1)
ターゲット用アンチセンスRNA
5’-GUUGUCAUACUUCUCAUGGUU-3’ (配列番号2)
コントロール用センスRNA
5’-UACUAUUCGACACGCGAAGUU-3’ (配列番号3)
コントロール用アンチセンスRNA
5’-CUUCGCGUGUCGAAUAGUAUU-3’ (配列番号4)
得られた各一本鎖RNAについて、前記実施例1と同様にして、分子量を測定した。下記表1に、測定した分子量(Observed mass)および理論上の算出値(Calculated mass)を併せて示す。なお、理論上の算出値は、使用したH2 18Oの18O純度99.2%を考慮して求めた。
得られた各一本鎖RNAについて、下記条件のHPLCによって純度を分析した。前記純度は、前記HPLCにおける全ピーク面積を100%とし、前記各一本鎖RNAの理論分子量に該当するリテンションタイムにおけるピーク面積の割合で示す。
分析装置:Shimadzu LC-10A system(島津製作所)
カラム:XBridge OST C18, 2.5μm(Waters)
カラムサイズ:4.6×50mm
溶出液:
A:50mmol/L 酢酸トリエチルアンモニウム(pH7.4) + 5% アセトニトリル
B:50mmol/L 酢酸トリエチルアンモニウム(pH7.4) + 50% アセトニトリル
グラジェント:%B 5%→10%/20min
流速:1.0 mL/min
検出器:UV検出器(254nm)
得られた各一本鎖RNAを組合せて、以下に示すように、二本鎖RNAを形成した。
(c1)前記コントロール用16O‐センスRNAと前記コントロール用16O‐アンチセンスRNAとの組み合わせ(16O/16O)
(c2)前記コントロール用16O‐センスRNAと前記コントロール用18O‐アンチセンスRNAとの組み合わせ(16O/18O)
(c3)前記コントロール用18O‐センスRNAと前記コントロール用16O‐アンチセンスRNAとの組み合わせ(18O/16O)
(c4)前記コントロール用18O‐センスRNAと前記コントロール用18O‐アンチセンスRNAとの組み合わせ(18O/18O)
(t1)前記ターゲット用16O‐センスRNAと前記ターゲット用16O‐アンチセンスRNAとの組み合わせ(16O/16O)
(t2)前記ターゲット用16O‐センスRNAと前記ターゲット用18O‐アンチセンスRNAとの組み合わせ(16O/18O)
(t3)前記ターゲット用18O‐センスRNAと前記ターゲット用16O‐アンチセンスRNAとの組み合わせ(18O/16O)
(t4)前記ターゲット用18O‐センスRNAと前記ターゲット用18O‐アンチセンスRNAとの組み合わせ(18O/18O)
前記(4)における各siRNAについて、円偏光二色性スペクトル(CDスペクトル)により、構造を比較した。測定は、分光偏光計(商品名J-720W、ジャスコインターナショナル)を用いて行った。図4に、CDスペクトルの結果を示す。図4には、前記(c1)~(c4)および(t1)~(t4)のsiRNAのうち、前記(c4)コントロール用siRNA(18O/18O)および前記(t4)ターゲット用siRNA(18O/18O)の結果を示した。図4において、縦軸が、ellipticity(分子楕円率)(ミリ度:mdeg)であり、横軸が、波長(nm)である。図4(A)は、前記(c4)コントロール用siRNA(18O/18O)の結果であり、図4(B)は、前記(t4)ターゲット用siRNA(18O/18O)の結果である。
前記(4)における各siRNAについて、熱力学的安定性を確認した。前記熱力学的安定性(Tm値)は、分光光度計(商品名UV-1800 UV-VIS、島津製作所)により測定した。
前記(4)における各siRNAについて、ヒトGAPDH遺伝子のmRNA発現量を測定し、発現抑制能を確認した。
GAPDH遺伝子増幅用プライマーセット
5’-GGAGAAGGCTGGGGCTCATTTGC-3’ (配列番号5)
5’-TGGCCAGGGGTGCTAAGCAGTTG-3’ (配列番号6)
β-アクチン遺伝子増幅用プライマーセット
5’-GCCACGGCTGCTTCCAGCTCCTC-3’ (配列番号7)
5’-AGGTCTTTGCGGATGTCCACGTCAC-3’ (配列番号8)
前記実施例1で合成した18O標識化ポリ(U)について、血清中濃度の測定を行った。
δ18O(‰)=[R(s)/R(r)-1]×1000
前記実施例2で合成した18Oを導入したsiRNAについて、安定同位体顕微鏡を用いて、細胞内局在を観察した。
前記実施例2で調製した前記18O-センスRNAと18O-アンチセンスRNAとを組合せた前記(c4)コントロール用siRNA(18O/18O)を使用した。
7mm×7mmのシリコンウェハーを、35mmディッシュの中央に置いた。前記ディッシュに、ヒト肺由来A549細胞を5×105cells/ディッシュとなるように播種し、培養した。培養条件は、37℃、5%CO2、24時間とした。培地は、10%FCS含有Dulbecco’s modified eagle medium(DMEM)(sigma)を使用した。培養後、2mLの新しい培地に交換し、siRNAを最終濃度300nmol/Lとなるように添加し、トランスフェクション試薬(商品名Lipofectamin2000、Invitrogen社製)を用いて、トランスフェクションした。前記トランスフェクション後、さらに、24時間培養した。前記培養後の細胞をPBSで洗浄し、2.5%グルタルアルデヒド/PBS溶液で、37℃、1時間処理して、前記細胞を固定した。その後、前記固定した細胞を、20、40、60、70、80、90、100%エタノールに、この順序で10分間ずつ浸すことで、脱水した。そして、tert-ブタノールを前記脱水後の細胞に添加し、冷凍庫で凍結後、乾燥した。前記凍結乾燥物に、厚さ30nmの金コーティングを施した。このようにして、サンプルを作製した。
前記サンプルを、安定同位体顕微鏡システム(北海道大学、Cameca ims-1270+SCAPS)で観察した。前記観察において、一次ビームとしてセシウムを使用し、12C14N、16O、18Oの2次イオンイメージを得た。この観察結果を、図7に示す。図7は、前記コントロール用siRNA(18O/18O)の細胞内局在を観察した顕微鏡写真である。図7において、左上の写真は、16Oの2次イオンイメージであり、左下の写真は、12C14Nの2次イオンイメージであり、右上の写真は、18Oの2次イオンイメージであり、右下の写真は、18O/16Oの2次イオンイメージである。
Claims (22)
- 3価リン化合物を、同位体を含む酸化剤で酸化することによって、前記同位体が導入された5価のリン酸化合物を合成する酸化工程を含むことを特徴とする、同位体含有リン酸化合物の製造方法。
- 前記酸化剤による酸化反応が、前記3価リン化合物における3価リンを5価リンに酸化し、且つ、前記5価リンに前記酸化剤由来の原子を結合させる酸化反応であり、
前記酸化剤が、前記5価リンに結合する前記原子として、前記同位体を有する、請求項1記載の製造方法。 - 前記同位体が、安定同位体である、請求項1または2記載の製造方法。
- 前記同位体が、17O、18O、33S、34S、36Sおよび10Bからなる群から選択された少なくとも一つの同位体である、請求項1から3のいずれか一項に記載の製造方法。
- 前記酸化剤が、酸素供与体であり、供与される酸素が、前記同位体である、請求項1から4のいずれか一項に記載の製造方法。
- 前記酸素供与体が、水またはペルオキシドである、請求項5記載の製造方法。
- 前記ペルオキシドが、ヒドロペルオキシドである、請求項6記載の製造方法。
- 前記ヒドロペルオキシドが、t-ブチルヒドロペルオキシドである、請求項7記載の製造方法。
- 前記酸化剤が、硫黄供与体であり、供与される硫黄が、前記同位体である、請求項1から4のいずれか一項に記載の製造方法。
- 前記硫黄供与体が、3H-1,2-ベンゾジチオール3-オン1,1-ジオキシドおよび5-((ジメチルアミノ-メチリデン)アミノ)-3H-1,2,4-ジチアゾール-3-チオンの少なくとも一方である、請求項9記載の製造方法。
- 前記酸化剤が、ホウ素供与体であり、供与されるホウ素が、前記同位体である、請求項1から4のいずれか一項に記載の製造方法。
- 前記ホウ素供与体が、アミン・ボラン複合体である、請求項11記載の製造方法。
- 前記アミン・ボラン複合体が、トリアルキルアミン・ボラン複合体である、請求項12記載の製造方法。
- 前記トリアルキルアミン・ボラン複合体が、ジイソプロピルエチルアミン・ボラン複合体である、請求項13記載の製造方法。
- 前記3価リン化合物が、亜リン酸エステルである、請求項1から14のいずれか一項に記載の製造方法。
- 前記3価リン化合物は、前記3価リンを有するヌクレオシドを含むモノマーであり、
前記ヌクレオシドは、糖と塩基を含み、前記糖の1’位に前記塩基が結合し、
前記糖に前記3価リンが結合している、請求項1から15のいずれか一項に記載の製造方法。 - 前記糖の5’位、3’位または2’位に前記3価リンが結合している、請求項16記載の製造方法。
- 前記3価リン化合物は、2以上のヌクレオシド残基を含むポリマーであり、
前記ヌクレオシド残基は、糖と塩基を含み、前記糖の1’位に前記塩基が結合し、
前記ヌクレオシド残基間は、それぞれの糖が、リンを介して結合し、
少なくとも一組のヌクレオシド残基間のリンが、前記3価リンである、請求項1から15のいずれか一項に記載の製造方法。 - 前記ヌクレオシド残基間は、一方の糖の5’位、3’位または2’位と、他方の糖の5’位、3’位または2’位とにおいて、前記リンを介して結合している、請求項18記載の製造方法。
- さらに、ヌクレオシドを含む2分子のモノマーをカップリングして、前記3価リン化合物を合成するカップリング工程を有し、
前記酸化工程において、前記カップリング工程により得られた前記3価リン化合物を、前記酸化剤により酸化して、前記同位体が導入された5価のリン酸化合物を合成する、請求項1から19のいずれか一項に記載の製造方法。 - さらに、前記5価のリン酸化合物に、ヌクレオシドを含むモノマーをカップリングして、前記3価のリン化合物を合成するカップリング工程を有し、
前記酸化工程において、前記カップリング工程により得られた前記3価リン化合物を、前記酸化剤により酸化して、前記同位体が導入された5価のリン酸化合物を合成する、請求項1から20のいずれか一項に記載の製造方法。 - 前記5価のリン酸化合物が、農薬、医薬またはリン脂質である、請求項1から21のいずれか一項に記載の製造方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2834665A CA2834665C (en) | 2011-05-10 | 2012-05-07 | Process for preparing phosphate compound bearing isotope |
BR112013028788A BR112013028788A2 (pt) | 2011-05-10 | 2012-05-07 | processo para a preparação de composto de fosfato contendo isótopo |
AU2012254580A AU2012254580B2 (en) | 2011-05-10 | 2012-05-07 | Process for preparing phosphate compound bearing isotope |
EP12782845.7A EP2722335A4 (en) | 2011-05-10 | 2012-05-07 | PROCESS FOR PRODUCING PHOSPHATE COMPOUND HAVING ISOTOPES |
CN201280022384.6A CN103517913A (zh) | 2011-05-10 | 2012-05-07 | 具有同位素的磷酸化合物的制造方法 |
EP18152148.5A EP3348564A1 (en) | 2011-05-10 | 2012-05-07 | Process for preparing phosphate compound bearing isotope |
US14/116,763 US9315799B2 (en) | 2011-05-10 | 2012-05-07 | Process for preparing phosphate compound bearing isotope |
MX2013013066A MX345065B (es) | 2011-05-10 | 2012-05-07 | Proceso para preparar un compuesto de fosfato marcado con isotopos. |
JP2013514004A JP5973425B2 (ja) | 2011-05-10 | 2012-05-07 | 同位体を有するリン酸化合物の製造方法 |
KR1020137029455A KR102097053B1 (ko) | 2011-05-10 | 2012-05-07 | 동위체를 갖는 인산 화합물의 제조 방법 |
IL229256A IL229256A (en) | 2011-05-10 | 2013-11-05 | A process for preparing an isotope-bearing phosphate compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011105722 | 2011-05-10 | ||
JP2011-105722 | 2011-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012153704A1 true WO2012153704A1 (ja) | 2012-11-15 |
Family
ID=47139183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/061652 WO2012153704A1 (ja) | 2011-05-10 | 2012-05-07 | 同位体を有するリン酸化合物の製造方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9315799B2 (ja) |
EP (2) | EP2722335A4 (ja) |
JP (1) | JP5973425B2 (ja) |
KR (1) | KR102097053B1 (ja) |
CN (3) | CN103517913A (ja) |
AU (1) | AU2012254580B2 (ja) |
BR (1) | BR112013028788A2 (ja) |
CA (1) | CA2834665C (ja) |
HK (1) | HK1257846A1 (ja) |
IL (1) | IL229256A (ja) |
MX (1) | MX345065B (ja) |
WO (1) | WO2012153704A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749402B (zh) * | 2016-11-25 | 2019-03-15 | 厦门大学 | 一种稳定同位素标记手性磷试剂及其制备方法与应用 |
BR112020001412A2 (pt) | 2017-07-28 | 2020-08-04 | Kyorin Pharmaceutical Co., Ltd. | inibidor de fosforilação da proteína smad2/3, agente terapêutico para fibrose, e, moléculas de ácido nucleico de fita dupla e de fita simples. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5003097A (en) * | 1989-10-02 | 1991-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the sulfurization of phosphorous groups in compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177198A (en) * | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US6017700A (en) * | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
CN100483101C (zh) * | 2003-09-17 | 2009-04-29 | 中国科学院青海盐湖研究所 | 硼同位素热电离质谱测定中氰酸根干扰的消除方法 |
CN100398515C (zh) * | 2004-12-17 | 2008-07-02 | 上海化工研究院 | 同位素15n标记l-天冬酰胺的合成方法 |
US20090142849A1 (en) * | 2007-10-05 | 2009-06-04 | University Of Connecticut | Stable Oxygen Isotope Labeling of Pre-existing Phosphoryl Groups on Phosphomolecules for Modification-Specific Mass Spectrometry |
-
2012
- 2012-05-07 WO PCT/JP2012/061652 patent/WO2012153704A1/ja active Application Filing
- 2012-05-07 CN CN201280022384.6A patent/CN103517913A/zh active Pending
- 2012-05-07 BR BR112013028788A patent/BR112013028788A2/pt not_active Application Discontinuation
- 2012-05-07 JP JP2013514004A patent/JP5973425B2/ja not_active Expired - Fee Related
- 2012-05-07 EP EP12782845.7A patent/EP2722335A4/en not_active Withdrawn
- 2012-05-07 EP EP18152148.5A patent/EP3348564A1/en not_active Withdrawn
- 2012-05-07 CA CA2834665A patent/CA2834665C/en not_active Expired - Fee Related
- 2012-05-07 MX MX2013013066A patent/MX345065B/es active IP Right Grant
- 2012-05-07 KR KR1020137029455A patent/KR102097053B1/ko active IP Right Grant
- 2012-05-07 AU AU2012254580A patent/AU2012254580B2/en not_active Ceased
- 2012-05-07 US US14/116,763 patent/US9315799B2/en not_active Expired - Fee Related
- 2012-05-07 CN CN201711002541.8A patent/CN107759650A/zh active Pending
- 2012-05-07 CN CN201711001586.3A patent/CN107814673A/zh active Pending
-
2013
- 2013-11-05 IL IL229256A patent/IL229256A/en active IP Right Grant
-
2019
- 2019-01-07 HK HK19100203.2A patent/HK1257846A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5003097A (en) * | 1989-10-02 | 1991-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the sulfurization of phosphorous groups in compounds |
Non-Patent Citations (4)
Title |
---|
ADRIAN P. HIGSON ET AL.: "Synthesis of an Oligothymidylate Containing Boranophosphate Linkages", TETRAHEDRON LETTERS, vol. 39, no. 23, 1998, pages 3899 - 3902, XP004118769 * |
J. ORG. CHEM., vol. 73, no. 1, 4 January 2008 (2008-01-04), pages 309 - 311 |
See also references of EP2722335A4 |
WOJCIECH J. STEC ET AL.: "Automated Solid-Phase Synthesis, Separation, and Stereochemistry of Phosphorothioate Analogues of Oligodeoxyribonucleotides", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 106, no. 20, 1984, pages 6077 - 6079, XP002410447 * |
Also Published As
Publication number | Publication date |
---|---|
MX345065B (es) | 2017-01-16 |
JP5973425B2 (ja) | 2016-08-23 |
MX2013013066A (es) | 2014-08-01 |
EP2722335A4 (en) | 2014-10-15 |
KR102097053B1 (ko) | 2020-04-03 |
JPWO2012153704A1 (ja) | 2014-07-31 |
CA2834665A1 (en) | 2012-11-15 |
HK1257846A1 (zh) | 2019-11-01 |
CN107814673A (zh) | 2018-03-20 |
US20140100362A1 (en) | 2014-04-10 |
KR20140019435A (ko) | 2014-02-14 |
EP2722335A1 (en) | 2014-04-23 |
CN103517913A (zh) | 2014-01-15 |
AU2012254580A1 (en) | 2013-11-14 |
CN107759650A (zh) | 2018-03-06 |
US9315799B2 (en) | 2016-04-19 |
CA2834665C (en) | 2019-08-20 |
IL229256A (en) | 2016-10-31 |
BR112013028788A2 (pt) | 2016-11-29 |
AU2012254580B2 (en) | 2016-11-17 |
IL229256A0 (en) | 2014-01-30 |
EP3348564A1 (en) | 2018-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abdur Rahman et al. | Design, synthesis, and properties of 2 ‘, 4 ‘-BNANC: a bridged nucleic acid analogue | |
Li et al. | Nucleoside and oligonucleoside boranophosphates: chemistry and properties | |
ES2349129T3 (es) | Polinucleótido que contiene un mimético de fosfato. | |
JP5715560B2 (ja) | mRNA CAP類似体 | |
Höbartner et al. | Chemical synthesis of selenium-modified oligoribonucleotides and their enzymatic ligation leading to an U6 SnRNA stem− loop segment | |
Jemielity et al. | Synthetic mRNA cap analogs with a modified triphosphate bridge–synthesis, applications and prospects | |
Sergueev et al. | H-Phosphonate approach for solid-phase synthesis of oligodeoxyribonucleoside boranophosphates and their characterization | |
CN102282155A (zh) | 磷原子修饰的核酸的合成方法 | |
JP2013520438A (ja) | 逆方向合成rnaのためのホスホルアミダイト | |
JP2015524820A (ja) | 重水素化したリボヌクレオシド、n保護ホスホロアミダイト、およびオリゴヌクレオチドの合成 | |
EP3864151A2 (en) | Enzymatic rna synthesis | |
Mikami et al. | Synthesis, chirality-dependent conformational and biological properties of siRNAs containing 5′-(R)-and 5′-(S)-C-methyl-guanosine | |
JP5973425B2 (ja) | 同位体を有するリン酸化合物の製造方法 | |
WO2016152980A1 (ja) | オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法 | |
Röthlisberger et al. | RNA chemistry for RNA biology | |
EP3484907B1 (en) | Novel phosphotriazole mrna 5'-end cap analogs, composition comprising the same, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule, protein or peptide | |
Sarac et al. | Solid‐phase synthesis of DNA and RNA 5′‐O‐triphosphates using cycloSal chemistry | |
Slott et al. | MicroRNA Pools Synthesized Using Tandem Solid-Phase Oligonucleotide Synthesis | |
Engels et al. | Chemical synthesis of 2′-O-alkylated siRNAs | |
Wu | Synthetic Nucleic Acid Capable of Post-Polymerization Functionalization and Evolution | |
JP2005046073A (ja) | 修飾核酸を用いるrna転写および/または増幅方法 | |
Lin | Synthesis, structure, function and biomedical studies of nucleic acid derivatized with selenium | |
CN101735298A (zh) | 一种磷酸二酯及其制备方法 | |
JP2010189276A (ja) | オリゴヌクレオチド誘導体、オリゴヌクレオチド誘導体を用いたオリゴヌクレオチド構築物、オリゴヌクレオチド誘導体を合成するための化合物及びオリゴヌクレオチド誘導体の製造方法 | |
Palmer | C) Copyright by Alison Lesley Palmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12782845 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013514004 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2834665 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20137029455 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/013066 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14116763 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012254580 Country of ref document: AU Date of ref document: 20120507 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012782845 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013028788 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013028788 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131108 |